The Future of Aspirin Therapy in Cardiovascular Disease.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
21
11
2020
accepted:
11
12
2020
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
10
4
2021
Statut:
ppublish
Résumé
Much has been written about the demise of aspirin (ASA) but reports of its death are premature. The drug remains one of the most widely prescribed by physicians worldwide. It is cheap, familiar, and effective for a variety of uses, including in patients with acute or prior myocardial infarction, ischemic stroke, peripheral artery disease, and percutaneous or surgical revascularization procedures, as well as for use for pain and fever relief. Beyond physician prescription or recommendation, over the counter use of ASA is common, including for primary cardiovascular prevention, though this decision really should involve a discussion of risks and benefits with a physician. ASA is an essential member of the duo that makes up dual antiplatelet therapy (a P2Y
Identifiants
pubmed: 33706989
pii: S0002-9149(20)31346-1
doi: 10.1016/j.amjcard.2020.12.019
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S40-S47Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.